Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early oral step-down versus continued intravenous antibiotics for uncomplicated gram-negative bacteremia
MOH_2023-05-02_012597Phase 3Not yet recruiting
- Sponsor
- Tan Tock Seng Hospital
- Start
- May 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trimethoprim + sulfamethoxazole and ciprofloxacin in gram-negative bacteremia (2 arms), sponsored by Tan Tock Seng Hospital. Primary endpoint: 30-day mortality. Planned start May 2023; status: not yet recruiting.
02
Drugs
trimethoprim + sulfamethoxazoleciprofloxacin
03
Conditions
gram-negative bacteremia
Beyond the preview
Go deeper on MOH_2023-05-02_012597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-02_012597.